University of Colorado Anschutz

06/03/2026

Campus in June. 🌼🌿

06/02/2026

Pancreatic cancer remains one of the most difficult cancers to treat. Now, a new drug called daraxonrasib has shown promising results, nearly doubling overall survival in patients with advanced pancreatic cancer compared with standard chemotherapy in a Phase 3 clinical trial.

The next step is FDA approval before the treatment can become more widely available to patients. oncologist Christopher Lieu, MD, spoke with The Conversation US to explain how this drug works and what comes next for patients.

🔗: https://bit.ly/4uWBtOD

05/31/2026

The Rocky Mountain MS Center at is home to one of the largest multiple sclerosis research programs in the world.

From basic science discoveries to clinical trials and emerging therapies, CU Anschutz researchers are helping advance our understanding of MS and improve care for people living with the disease. 🧠

Explore some of the latest MS research and discoveries from our campus: https://bit.ly/3FlN5pA

05/29/2026

How did PCOS become PMOS?

In The Conversation US, endocrinologist Melanie Cree, MD, PhD, explains the decade-long international effort to rename the condition, why the change matters, and what it could mean for diagnosis, treatment and care for millions of people worldwide. ⬇️

Polycystic o***y syndrome is an inaccurate name for a condition that affects millions of people worldwide. Its new name can help address missed diagnoses and fragmented care.

05/27/2026

We are thrilled to share that a $15 million gift from Lyda T. Ludeman will launch the Pioneering Research and Innovation in Science and Medicine for Women (PRISM) program at the Ludeman Family Center for Women’s Health Research.

The PRISM program will intentionally link research, innovation and clinical care through a coordinated, phased approach. The goal: to ensure research insights directly inform patient outcomes.

05/26/2026

How would you convince a room of strangers you had the next great idea in healthcare in under 10 minutes?

At the 2026 CU Anschutz Innovation Forum’s Innovation Fast Pitch session, four startup teams participated in a rapid-fire presentation showcase competing for an award of $10,000.

The contenders focused on a mix of healthcare solutions, including making mental health more responsive, developing a device to more effectively deliver therapeutics to the kidneys, identifying biomarkers for mental health conditions and addressing dementia by reversing hearing loss.

Find out who the audience chose as their winner. 👇 💰

A 'Shark Tank' style event with audience voting took place at CU Anschutz, highlighting the work of four startup ventures of campus faculty.

05/25/2026

Today, we pause to remember and honor the service members who gave their lives in service to our country. We wish you and your loved ones a safe and meaningful Memorial Day. 🇺🇸

Below: A Memorial Day ceremony takes place in front of the Fitzsimons Building, 1944.

05/24/2026

For more than 125 years, the University of Colorado Anschutz College of Nursing has prepared the next generation of nurses through compassionate care and hands-on learning. Home to the Rocky Mountain region’s largest nursing simulation center, we’re advancing patient-centered care with immersive training and research.

This National Nurses Month, we celebrate the nurses across our campus and the students preparing to make a difference in healthcare for years to come. 💛

05/23/2026

This one goes out to the support systems behind the degrees. 🎓

05/22/2026

What if the future of obesity treatment came in a pill instead of an injection? 💊

researchers are helping lead a clinical trial studying orforglipron, a first-of-its-kind oral GLP-1 medication. Early results showed meaningful weight loss across tested doses, while researchers continue working to better understand why some patients respond differently to GLP-1 therapies and how more affordable, accessible options could expand care. ⬇️

Orforglipron is an FDA-approved non-peptide oral GLP-1 pill, an alternative to injectable weight-loss drugs. Demand for GLP-1s has surged, but cost and injectable delivery have limited access. A CU Anschutz researcher is leading a clinical trial for orforglipron, and a patient shares her trial exper...